Comparative Pharmacology
Head-to-head clinical analysis: ANTRENYL versus CANTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTRENYL versus CANTIL.
ANTRENYL vs CANTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antrenyl (oxyphenonium bromide) is a quaternary ammonium anticholinergic agent that competitively blocks acetylcholine at muscarinic receptors in smooth muscle, exocrine glands, and the CNS, leading to reduced gastrointestinal motility and secretion.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
50 mg orally 3 times daily initially, then adjust to 50-100 mg 3 times daily; 20 mg intramuscularly or intravenously every 4-6 hours as needed.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
None Documented
None Documented
2-4 hours (terminal), requiring q6-8h dosing for sustained anticholinergic effect
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Renal (80% as unchanged drug and metabolites), biliary/fecal (20%)
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Category C
Category C
Anticholinergic
Anticholinergic / Antispasmodic